Bleeding profiles and effects on the endometrium for women using a novel combination of transdermal oestradiol and natural progesterone cream as part of a continuous combined hormone replacement regime

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 112, Issue 10, 2005, Pages 1402-1406

  Vashisht, Arvind ^a,c   Wadsworth, Fred ^a   Carey, Adam ^a   Carey, Beverley ^a   Studd, John ^b  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b LISTER HOSPITAL   (United Kingdom)

^c NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; PROGESTELLE; PROGESTERONE;

ADULT; AMENORRHEA; ARTICLE; CREAM; DRUG TREATMENT FAILURE; ENDOMETRIUM; ENDOMETRIUM BIOPSY; FEMALE; HISTOLOGY; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MENSTRUATION; MITOGENESIS; POSTMENOPAUSE; PRIORITY JOURNAL; SELF REPORT; SPOTTING; THICKNESS; ULTRASOUND; UNITED KINGDOM; DRUG COMBINATION; DRUG EFFECT; INTRADERMAL DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; OINTMENT; PATIENT COMPLIANCE; UTERUS BLEEDING;

ADMINISTRATION, CUTANEOUS; DRUG COMBINATIONS; ENDOMETRIUM; ESTRADIOL; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; OINTMENTS; PATIENT COMPLIANCE; POSTMENOPAUSE; PROGESTERONE; UTERINE HEMORRHAGE;

EID: 32944480046     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2005.00689.x     Document Type: Article

References (41)

1. Fremont-Smith M, Meigs JV, Graham RM, et al. Cancer of the endometrium and prolonged estrogen therapy. JAMA 1946 131 : 805 808.
2. Mack TM, Pike MC, Henderson BE, et al. Estrogens and endometrial cancer in a retirement community. N Engl J Med 1976 294 : 1262 1267.
3. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975 293 : 1167 1170.
4. Thom MH, White PJ, Williams RM, et al. Prevention and treatment of endometrial disease in climacteric women receiving oestrogen therapy. Lancet 1979 2 : 455 457.
5. Sturdee DW, Wade-Evans T, Paterson ME, Thom M, Studd JW. Relations between bleeding pattern, endometrial histology, and oestrogen treatment in menopausal women. BMJ 1978 1 : 1575 1577.
6. Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999 91 : 1131 1137.
7. Magos AL, Brewster E, Singh R, O'Dowd T, Brincat M, Studd JW. The effects of norethisterone in postmenopausal women on oestrogen replacement therapy: a model for the premenstrual syndrome. Br J Obstet Gynacol 1986 93 : 1290 1296.
8. Hirvonen E, Malkonen M, Manninen V. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy. N Engl J Med 1981 304 : 560 563.
9. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002 288 (3 321 333.
10. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003 362 (9382 419 427.
11. de Lignieres B, De Vathaire F, Fournier S, et al. Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women. Climacteric 2002 5 (4 332 340.
12. Peterson CM. Progestogens, progesterone antagonists, progesterone, and androgens: synthesis, classification, and uses. Clin Obstet Gynecol 1995 38 : 813 820.
13. Anonymous. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995 273 (3 199 208 [see comments] [published erratum appears in JAMA 1995;274(21):1676 (December 6)].
14. Leonetti HB, Longo S, Anasti JN. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol 1999 94 : 225 228.
15. De Ziegler D, Ferriani R, Moraes LA, Bulletti C. Vaginal progesterone in menopause: crinone 4% in cyclical and constant combined regimens. Hum Reprod 2000 15 (Suppl 1 149 158.
16. Wren BG, McFarland K, Edwards L. Micronised transdermal progesterone and endometrial response. Lancet 1999 354 : 1447 1448.
17. Burry KA, Patton PE, Hermsmeyer K. Percutaneous absorption of progesterone in postmenopausal women treated with transdermal estrogen. Am J Obstet Gynecol 1999 180 : 1504 1511.
18. Paterson ME, Wade-Evans T, Sturdee DW, Thom MH, Studd JW. Endometrial disease after treatment with oestrogens and progestogens in the climacteric. BMJ 1980 280 (6217 822 824.
19. Gelfand MM, Ferenczy A. A prospective 1-year study of estrogen and progestin in postmenopausal women: effects on the endometrium. Obstet Gynecol 1989 74 : 398 402.
20. Schiff I, Sela HK, Cramer D, Tulchinsky D, Ryan KJ. Endometrial hyperplasia in women on cyclic or continuous estrogen regimens. Fertil Steril 1982 37 : 79 82.
21. Anonymous. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1996 275 : 370 375.
22. Paterson ME, Wade-Evans T, Sturdee DW, Thom MH, Studd JW. Endometrial disease after treatment with oestrogens and progestogens in the climacteric. BMJ 1980 280 : 822 824.
23. Hillard TC, Siddle NC, Whitehead MI, Fraser DI, Pryse-Davies J. Continuous combined conjugated equine estrogen-progestogen therapy: effects of medroxyprogesterone acetate and norethindrone acetate on bleeding patterns and endometrial histologic diagnosis. Am J Obstet Gynecol 1992 167 (1 1 7.
24. Leather AT, Savvas M, Studd JW. Endometrial histology and bleeding patterns after 8 years of continuous combined estrogen and progestogen therapy in postmenopausal women. Obstet Gynecol 1991 78 : 1008 1010.
25. Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group. Am J Obstet Gynecol 1994 170 : 1213 1223.
26. Sturdee DW, Ulrich LG, Barlow DH, et al. The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy. BJOG 2000 107 (11 1392 1400 (November).
27. Casanas-Roux F, Nisolle M, Marbaix E, Smets M, Bassil S, Donnez J. Morphometric, immunohistological and three-dimensional evaluation of the endometrium of menopausal women treated by oestrogen and Crinone, a new slow-release vaginal progesterone. Hum Reprod 1996 11 : 357 363.
28. Ross D, Cooper AJ, Pryse-Davies J, Bergeron C, Collins WP, Whitehead MI. Randomized, double-blind, dose-ranging study of the endometrial effects of a vaginal progesterone gel in estrogen-treated postmenopausal women. Am J Obstet Gynecol 1997 177 : 937 941.
29. Hargrove JT, Maxson WS, Wentz AC, Burnett LS. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. Obstet Gynecol 1989 73 : 606 612.
30. Cooper A, Spencer C, Whitehead MI, Ross D, Barnard GJ, Collins WP. Systemic absorption of progesterone from Progest cream in postmenopausal women. Lancet 1998 351 : 1255 1256.
31. Leonetti HB, Wilson KJ, Anasti JN. Topical progesterone cream has an antiproliferative effect on estrogen-stimulated endometrium. Fertil Steril 2003 79 (1 221 222.
32. Bolaji II, Mortimer G, Grimes H, Tallon DF, O'Dwyer E, Fottrell PF. Clinical evaluation of near-continuous oral micronized progesterone therapy in estrogenized postmenopausal women. Gynecol Endocrinol 1996 10 : 41 47.
33. Archer DF, Lobo RA, Land HF, Pickar JH. A comparative study of transvaginal uterine ultrasound and endometrial biopsy for evaluating the endometrium of postmenopausal women taking hormone replacement therapy. Menopause 1999 6 : 201 208.
34. Neven P, Lunde T, Benedetti-Panici P, et al. A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate. BJOG 2003 110 (2 157 167.
35. Granberg S, Wikland M, Karlsson B, Norstrom A, Friberg LG. Endometrial thickness as measured by endovaginal ultrasonography for identifying endometrial abnormality. Am J Obstet Gynecol 1991 164 : 47 52.
36. Karlsson B, Granberg S, Wikland M, et al. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding - a Nordic multicenter study. Am J Obstet Gynecol 1995 172 : 1488 1494.
37. Rozenberg S, Ylikorkala O, Arrenbrecht S. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids. Int J Fert Women's Med 1997 42 (Suppl 2 376 387.
38. Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group. Obstet Gynecol 1994 83 : 686 692.
39. Sturdee DW, Barlow DH, Ulrich LG, et al. Is the timing of withdrawal bleeding a guide to endometrial safety during sequential oestrogen-progestogen replacement therapy? UK Continuous Combined HRT Study Investigators. Lancet 1994 344 : 979 982.
40. Darj E, Nilsson S, Axelsson O, Hellberg D. Clinical and endometrial effects of oestradiol and progesterone in post-menopausal women. Maturitas 1991 13 : 109 115.
41. Warren MP, Biller BM, Shangold MM. A new clinical option for hormone replacement therapy in women with secondary amenorrhea: effects of cyclic administration of progesterone from the sustained-release vaginal gel Crinone (4% and 8%) on endometrial morphologic features and withdrawal bleeding. Am J Obstet Gynecol 1999 180 : 42 48.